The study involves gathering information via one-on-one patient interviews, surveys and questionnaires so that we can better understand the patient decision-making process involved in bladder cancer treatment.

This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.